Synpromics December Newsletter
No Images? Click here
Latest news from Synpromics
The leader in gene control
Synpromics' key partner, uniQure, has announced the incorporation of its promoter, developed by Synpromics, in a new preclinical research target to treat Hemophilia A. This follows recent positive data, presented at the ESGCT world congress, demonstrating that this highly selective liver promoter is at least eight times more potent than the current industry standard.
Synpromics Unveils Next Generation Liver Selective and Tunable Promoter Platform
Synpromics unveiled a novel drug-regulatable promoter platform at the ESGCT congress and showcased data generated from its innovative liver selective inducible and repressible synthetic promoter systems that are tightly controlled by FDA-approved small molecule drugs.
Synpromics Partners
Synpromics continues to work with biotech companies, large cap pharma and translational research institutions across the sector including 6 of the top 10 public gene medicine companies. Recent collaborations include Regeneron and Oxford Biomedica.
Technology Update - Accelerating the Development of Liver Gene Medicines
Synpromics has made significant recent progress in liver selective promoters for use in gene medicines to treat acute and chronic liver failure, as well as a variety of inborn errors of metabolism. Read more about our developments in Technology Networks.
Synpromics named among the top 50 fastest growing technology companies in the UK
Synpromics is the highest ranking Scottish company and healthcare/lifescience company, coming in 12th overall in the Deloitte UK Technology Fast 50 - one of the UK's foremost technology award programmes. This follows David Venables' success in the EY Entrepreneur Of The Year Awards.
Synpromics meet First Minister at the official opening of the Roslin Innovation Centre
The Scottish Government's Cabinet met for a cabinet meeting at the University of Edinburgh's Easter Bush campus and whilst there officially opened the Roslin Innovation Centre.
Investor Video: How Calculus Capital has helped Synpromics grow
In a recent video from one of our investors, David Venables discusses Synpromics’ disruptive technology and how it enables the control of genetic ‘switches’. Investment from Calculus Capital has allowed Synpromics to expand and provided further funding for R&D, driving deal value growth.
Busy year of conferences for Synpromics
As well as making some big announcements at ESGCT, Synpromics have attended a number of global conferences including hosting a standing room only symposium at ASGCT, ARM Meeting on the Mesa, BIO Europe, Biotech & Money Inv€$tival Showcase, Jeffries Healthcare Conference, Biopharm America, BIO and the ARM Cell & Gene Therapy Investor Day.
In case you missed it...
Labiotech - Top Ten Biotechs in Scotland to Watch Out For
Jonathan Smith presents the top ten biotechs in Scotland, based on their innovation and progress in the last two years. Published by Labiotech.
The Scotsman - Vision Scotland: Healthy options in a new age of enlightenment
Sandra Dick looks at Scottish companies at the cutting edge of life science research. Published by Johnston Press.
Nature Jobs - Transitioning from Academia to Industry
Flavia Scialpi, Head of Biology at Synpromics, discusses her transition to industry in a blog. Published by Jack Leeming for Nature Jobs.
JP Morgan Healthcare Conference
DATE: 7th - 10th January 2019 | LOCATION: San Francisco, US
ASGCT Annual Meeting
Date: 29th April - 2nd May 2019 | Location: Washington D.C, US
